

Effect-site targeted propofol for anaesthesia in children

Submission date 23/08/2010	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 22/02/2011	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 09/05/2017	Condition category Surgery	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Neil Morton

Contact details
Royal Hospital for Sick Children
Dalnair Street
Glasgow
United Kingdom
G3 8SJ

Additional identifiers

Clinical Trials Information System (CTIS)
2009-014568-21

Protocol serial number
EudraCT number: 2009-014568-21

Study information

Scientific Title
A multicentre open study of the performance of an effect-site targeted infusion of propofol used for induction and maintenance of anaesthesia in children under 16 years

Study objectives

The equilibration of propofol from the plasma compartment to brain can be described using the time to peak effect and keo values for propofol. This is an open study to determine the performance of an effect-site targeted infusion based on the age-dependent values described by Jeleazcov (2008), using the four standard measures of bias, precision, divergence and wobble. These derived parameters estimate quantitatively whether the system over- or under-delivers propofol and how this varies both between patients and for an individual patient over time.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multicentre open non-randomised non-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

General anaesthesia

Interventions

Patients will be recruited from suitable operating lists and after appropriate consent, will undergo induction and maintenance of general anaesthesia using the effect-site targeted infusion of propofol. Patients will have an intravenous (iv) cannula inserted through topically-anaesthetised skin and a bolus of remifentanyl 0.5 µg/kg and lignocaine 0.2 mg/kg will be injected to reduce propofol pain at induction. Bispectral index monitoring will be used to monitor depth of anaesthesia throughout the induction and maintenance period.

During the period of maintenance of anaesthesia, the target effect-site concentration will be lowered and a hysteresis loop of depth of anaesthesia against propofol concentration will be populated using the BIS data and plasma samples collected from a second venous cannula. From this, an estimate of the keo value for propofol can be calculated. The period of lightening of anaesthesia may be terminated at any point because of clinical or BIS-derived suspicions of a requirement for greater depth of anaesthesia. The main outcome measure of the performance of the infusion algorithm is calculated from propofol sampling performed during the remainder of the period of anaesthesia using non-linear mixed effects monitoring. A maximum of 5 ml blood will be sampled from each patient.

The involvement of each participant concludes at the time of emergence from anaesthesia.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Propofol

Primary outcome(s)

Performance of an effect-site target controlled infusion (TCI) pharmacokinetic model for children aged 1 to 12 years and weight 6 - 60 kg, as calculated from the four standard parameters described by Varvel et al. The performance error (PE) is calculated from the concentration of propofol measured in whole blood (C_{meas}) and the concentration predicted by the software (C_{pred}) as follows: $PE(\%) = ((C_{meas} - C_{pred}) / C_{pred}) \times 100$. Four standard measures of performance are derived from this value, namely bias, precision, divergence and wobble. These derived parameters estimate quantitatively whether the system over- or under-delivers propofol, and how this varies both between patients and for an individual patient over time.

Key secondary outcome(s)

1. Population pharmacokinetics of propofol in children aged 1 to 12 years using non-linear effects modelling (NONMEM). This allows the calculation of volume of distribution and clearance of propofol and potential relationships between these pharmacokinetic parameters and the variables of age, gender and weight to be explored.
2. Pharmacodynamic modelling, using bispectral index as a measure of depth of anaesthesia. This will allow direct estimation of the blood-brain equilibration rate-constant (ke₀) for propofol in this patient population.
3. Establish a safety profile for effect-site TCI propofol based on the pharmacodynamics of Jeleazcov et al by identifying the rate of adverse events associated with the use of effect-site targeted propofol infusion

Completion date

30/11/2011

Eligibility**Key inclusion criteria**

1. American Society of Anaesthesiologists (ASA) grade 1 and 2 healthy male and female children aged 1 to 12 years (inclusive)
2. Weight 6 - 60 kg
3. Elective surgery requiring general anaesthesia
4. Surgery or procedure of expected duration of at least 30 minutes
5. Written parental consent or child's consent if competent, for inclusion
6. Child appropriate for intravenous induction and maintenance of anaesthesia with propofol
7. Agreement to undergo intravenous induction of anaesthesia
8. No contraindication to application of topical local anaesthesia prior to cannulation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

1 years

Upper age limit

12 years

Sex

All

Key exclusion criteria

1. Parental refusal or refusal of child if competent
2. Allergy to propofol or any constituent of propofol
3. Sensitivity to adhesive agents, as used in the Bispectral Index (BIS) measurement strip
4. Refusal of intravenous induction
5. Need for sedative premedication
6. Inadequate topical analgesia for intravenous cannulation
7. Inability to site intravenous cannula within two attempts

Date of first enrolment

01/12/2010

Date of final enrolment

30/11/2011

Locations**Countries of recruitment**

United Kingdom

Scotland

Study participating centre

Royal Hospital for Sick Children

Glasgow

United Kingdom

G3 8SJ

Sponsor information**Organisation**

NHS Greater Glasgow and Clyde (UK)

ROR

<https://ror.org/05kdz4d87>

Funder(s)

Funder type

Research organisation

Funder Name

National Institute of Academic Anaesthesia (NIAA) (UK)

Funder Name

Yorkhill Children's Foundation (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration